BioNTech Stock Tanks As Outlook, Founder Exit Rattle Bulls

The company guided 2026 total revenue to roughly $2.2–$2.5 billion, which is below Street expectations. Management said COVID will be a smaller contributor going forward and that future growth will rely increasingly on the oncology pipeline, signaling greater execution risk tied to drug development outcomes.

Analysis

The company guided 2026 total revenue to roughly $2.2–$2.5 billion, which is below Street expectations. Management said COVID will be a smaller contributor going forward and that future growth will rely increasingly on the oncology pipeline, signaling greater execution risk tied to drug development outcomes.